Smith+Nephew Matches Q1 Estimates and Unveils $500M Buyback—Shares Slide

Smith+Nephew (LON: SN.) delivered a steady first-quarter update, meeting revenue expectations and launching a fresh $500 million share repurchase program. Despite reaffirming full-year guidance and highlighting robust growth in Sports Medicine, shares dropped and are currently down about 1.4% as markets fixated on targeted weakness within the US Knee Implants division.

Headline Numbers:

Revenue: The medical technology giant reported Q1 revenue of $1,501 million versus $1,407 million last year. This delivered underlying revenue growth of 3.1%, or a healthier 4.7% on an adjusted daily sales basis after accounting for one fewer trading day in the quarter.

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG

5.0

View Offers

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

Profit & Margins: Full-year margin expectations hold steady. The company remains on track to deliver trading profit growth on an organic basis of around 8%, translating to approximately $1.3 billion post-acquisition of Integrity Orthopaedics.

Cash & Balance Sheet: The cash pipeline remains highly supportive. Free cash flow generation is projected at around $800 million for the year, giving management extensive flexibility for both internal investment and shareholder rewards.

Management is aggressively utilizing capital returns to anchor the stock amidst segment transitions. The new $500 million share buyback, funded entirely from free cash flow and existing cash balances, follows a similar program completed in 2025. When combined with anticipated ordinary dividends, Smith+Nephew is slated to return over $835 million to shareholders over the next twelve months. This equates to a substantial 6.3% yield on the current market capitalization, underscoring leadership’s conviction in the balance sheet.

Driver Breakdown Box:

• Sports Medicine Milestone: Sports Medicine & ENT posted 6.7% underlying growth. Driven by double-digit gains in joint repair products like the REGENETEN implant, Sports Medicine is now officially larger than the Orthopaedic Reconstruction and Robotics division.
• Wound Care Transition: Advanced Wound Management saw a tepid 2.2% underlying growth rate. This division absorbed the brunt of an expected reimbursement reset for skin substitutes, which pressured volumes and pricing in non-surgical settings.
• Orthopaedic Drag: Total Orthopaedics managed just 0.8% underlying growth. The glaring weak spot was US Knee Implants, which plunged 10.3%. Management framed this as a deliberate trade-off to manage inventory ahead of the highly anticipated Q3 launch of the new kinematic LANDMARK Knee System.

AskTraders Takeaway: The pullback suggests markets are discounting the delayed gratification of second-half product launches. While the $500 million buyback limits downside risk, institutional capital appears hesitant to bid up the stock until the structural drag in US orthopaedics is demonstrably resolved.

CEO Deepak Nath stated, “First-quarter performance was in line with our expectations, with strong execution in Sports Medicine and solid performance in Advanced Wound Management and the rest of Orthopaedics offsetting the anticipated softness in US knees, reflecting the resilience and balance of our portfolio,” reinforcing the company’s RISE strategy and focus on scaling high-growth innovations.